Status:
UNKNOWN
Efficacy and Safety Morus Alba L. Extract on Improvement of Blood Flow
Lead Sponsor:
Chonbuk National University Hospital
Conditions:
Blood Flow
Eligibility:
All Genders
50-75 years
Phase:
NA
Brief Summary
The effect of 12 weeks intake of Morus alba L. on blood circulation improvement and related indicators is assessed compared to placebo intake.
Detailed Description
This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. Hundred subjects were randomly divided into Morus alba L. extract or a placebo group. Blood was collected and chang...
Eligibility Criteria
Inclusion
- Those with a fasting total cholesterol of 200\~239 mg/dL
- Those with a fasting LDL-cholesterol of 130\~159 mg/dL
- Those with a fasting blood sugar of 100\~125 mg/dL
- Those with a SBP of 120\~139 mmHg
- Those with a BMI of 25\~29.9 kg/m\^2
- Waist Hip Ratio (WHR) is 0.9 or more for males and 0.85 or more for females
Exclusion
- Those with platelet aggregation and significant disability
- The platelet count is less than 100,000/μL or more than 500,000/μL
- The Hematocrit is less than 25%
- BMI is less than 18.5kg/m\^2 or greater than 30kg/m\^2
- Those with clinically significant severe cardiovascular, endocrine, immune, respiratory, liver, biliary, renal and urinary tract, neuropsychiatry, musculoskeletal, inflammatory and hematologic and gastrointestinal disorders
- Those with a history of clinically significant hypersensitivity to mulberry
- Those who have been taking platelet function, blood circulation improvement and hyperlipidemia related medicines, health functional food or herbal medicine continuously for more than 7 days within one month before screening
- Those who have received antipsychotic medication within 2 months before screening
- Those who participated in other clinical trials within 3 months before screening
- Women receiving hormone replacement therapy
- Laboratory test by show the following results
- AST, ALT \> Reference range 3 times upper limit
- Serum Creatinine \> 2.0 mg/dL
- Pregnancy or breast feeding
- Those who doesn't accept the implementation of appropriate contraception of a childbearing woman
- Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.
Key Trial Info
Start Date :
November 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03807570
Start Date
November 12 2018
End Date
January 31 2021
Last Update
May 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Center for Functional Foods Chonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea, 54907